TBPMF News and Press, Tetra Bio-Pharma Inc From 04/01/21

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB...

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor ȁ...

Tetra Bio-Pharma (TBPMF) announces that Health Canada supports the filing of a Clinical Trial Application ((CTA)) for assessing their novel drug candidate, ARDS-003, in patients with COVID-19. Tetra's trial will be the first worldwide drug which involves the use of an injectable sterile ...

Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS ARDS is the leading cause of mortality in patients with COVID-19 and develops in 20-67%...

Tetra Bio-Pharma (TBPMF) initiates research projects with Targeted Pharmaceuticals to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications. The global central nervous system drugs market is expected to grow from $125.28B in 2020 to $163.05B in 2...

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 202...

Quantum Pharma Inc. is a contract facility operated by Tetra Bio-Pharma Inc Quantum Pharma Inc. receives a Notice of Compliant rated inspection OTTAWA, ON / ACCESSWIRE / March 18, 2021 / Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) ...

Reduvo™ would be Canada's only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / March 15, 2021 / Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pi...

OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In ...

OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) , a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr. Guy Chamberland will present a company overview and hold virtual inves...